Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report published on Monday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 6.0 %

Shares of BTX opened at $0.27 on Monday. The stock has a market cap of $15.98 million, a PE ratio of -0.12 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The stock has a 50 day simple moving average of $0.78 and a 200-day simple moving average of $1.38.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.